Skip to content
TrialScanner

NCT06443944

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

No phase registeredAvailableCGONLead

Registry record

Lead sponsor
CG Oncology, Inc.
Conditions
Non-Muscle Invasive Bladder Cancer; Urothelial Carcinoma; Urologic Cancer; Bladder Cancer
Primary completion
Not registered
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT06443944 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT06443944: An Expanded Access Program... | TrialScanner